**Supplemental Table 1. Diagnostic performance of LSM for dichotomized fibrosis stage as determined by liver biopsy for patients with reliable VCTE scans, NAFLD patients, and non-NAFLD patients**

| **Patient group** | **Fibrosis stages** | **AUROC (95% CI)** | **LSM cut-off in kPa** | **Sensitivity** | **Specificity** | **PPV\*** | **NPV†** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Reliable VTCE only, Youden’s index (*n*=102) | Stage 0 vs. 1-4 | 0.73 (0.63-0.83) | 11.55 | 0.51 | 0.91 | 0.92 | 0.48 |
| Stage 0-1 vs. 2-4 | 0.79 (0.69-0.88) | 11.45 | 0.67 | 0.84 | 0.78 | 0.76 |
| Stage 0-2 vs. 3-4 | 0.86 (0.79-0.93) | 10.75 | 0.93 | 0.70 | 0.54 | 0.96 |
| Stage 0-3 vs. 4 | 0.89 (0.81-0.98) | 11.45 | 1.00 | 0.67 | 0.23 | 1.00 |
| Reliable VTCE only, sensitivity=0.90 (*n*=102) | Stage 0 vs. 1-4 |  | 5.35 | 0.90 | 0.29 | 0.72 | 0.60 |
| Stage 0-1 vs. 2-4 |  | 6.35 | 0.90 | 0.36 | 0.53 | 0.81 |
| Stage 0-2 vs. 3-4 |  | 10.75 | 0.90 | 0.70 | 0.53 | 0.95 |
| Stage 0-3 vs. 4 |  | 11.45 | 0.90 | 0.68 | 0.21 | 0.99 |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Reliable VTCE only, specificity=0.90 (*n*=102) | Stage 0 vs. 1-4 |  | 11.55 | 0.52 | 0.90 | 0.91 | 0.48 |
| Stage 0-1 vs. 2-4 |  | 14.05 | 0.60 | 0.90 | 0.83 | 0.73 |
| Stage 0-2 vs. 3-4 |  | 20.45 | 0.46 | 0.90 | 0.64 | 0.82 |
| Stage 0-3 vs. 4 |  | 24.50 | 0.56 | 0.90 | 0.35 | 0.95 |
| NAFLD patients, Youden’s index (*n*=49) | Stage 0 vs. 1-4 | 0.67 (0.50-0.85) | 11.7 | 0.57 | 0.83 | 0.91 | 0.38 |
| Stage 0-1 vs. 2-4 | 0.83 (0.72-0.95) | 12.3 | 0.76 | 0.88 | 0.86 | 0.78 |
| Stage 0-2 vs. 3-4 | 0.93 (0.87-1.00) | 12.3 | 0.94 | 0.81 | 0.73 | 0.96 |
| Stage 0-3 vs. 4 | 0.90 (0.79-1.00) | 20.45 | 0.83 | 0.88 | 0.50 | 0.97 |
| NAFLD patients, sensitivity=0.90 (*n*=49) | Stage 0 vs. 1-4 |  | 5.35 | 0.90 | 0.33 | 0.81 | 0.52 |
| Stage 0-1 vs. 2-4 |  | 7.15 | 0.90 | 0.50 | 0.65 | 0.83 |
| Stage 0-2 vs. 3-4 |  | 12.30 | 0.90 | 0.81 | 0.72 | 0.94 |
| Stage 0-3 vs. 4 |  | 13.20 | 0.90 | 0.67 | 0.27 | 0.98 |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| NAFLD patients, specificity=0.90 (*n*=49) | Stage 0 vs. 1-4 |  | 20.45 | 0.24 | 0.90 | 0.88 | 0.28 |
| Stage 0-1 vs. 2-4 |  | 14.10 | 0.70 | 0.90 | 0.88 | 0.74 |
| Stage 0-2 vs. 3-4 |  | 14.75 | 0.82 | 0.90 | 0.81 | 0.91 |
| Stage 0-3 vs. 4 |  | 23.35 | 0.50 | 0.90 | 0.41 | 0.93 |
| Non-NAFLD patients, Youden’s index (*n*=60) | Stage 0 vs. 1-4 | 0.76  (0.64 – 0.88) | 12.3 | 0.49 | 0.96 | 0.95 | 0.54 |
| Stage 0-1 vs. 2-4 | 0.78  (0.65 – 0.91) | 10.5 | 0.73 | 0.79 | 0.73 | 0.79 |
| Stage 0-2 vs. 3-4 | 0.83  (0.72 – 0.93) | 10.5 | 0.87 | 0.71 | 0.50 | 0.94 |
| Stage 0-3 vs. 4 | 0.92  (0.82 – 1.00) | 27.0 | 0.83 | 0.91 | 0.50 | 0.98 |
| Non-NAFLD patients, sensitivity=0.90 (*n*=60) | Stage 0 vs. 1-4 |  | 5.35 | 0.90 | 0.26 | 0.66 | 0.62 |
| Stage 0-1 vs. 2-4 |  | 5.35 | 0.90 | 0.21 | 0.46 | 0.73 |
| Stage 0-2 vs. 3-4 |  | 9.70 | 0.90 | 0.63 | 0.45 | 0.95 |
| Stage 0-3 vs. 4 |  | 11.35 | 0.90 | 0.70 | 0.25 | 0.98 |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Non-NAFLD patients, specificity=0.90 (*n*=60) | Stage 0 vs. 1-4 |  | 11.55 | 0.52 | 0.90 | 0.89 | 0.54 |
| Stage 0-1 vs. 2-4 |  | 13.50 | 0.58 | 0.90 | 0.82 | 0.74 |
| Stage 0-2 vs. 3-4 |  | 27.00 | 0.40 | 0.90 | 0.57 | 0.82 |
| Stage 0-3 vs. 4 |  | 27.00 | 0.83 | 0.90 | 0.48 | 0.98 |